The verdict
Our read at a glance.
Whether oxyntomodulin's natural dual GLP-1 and glucagon activity translates into a usable weight-loss treatment, versus serving mainly as the template for engineered dual agonists.
- The signal
- Short human studies show oxyntomodulin reduces appetite and food intake and modestly affects weight. Its very short duration in the body limits it as a drug, and most development has shifted to longer-acting dual agonists modeled on it. It is not approved.
- The unknown
- Whether oxyntomodulin itself, or longer-acting versions, can deliver meaningful weight loss with acceptable tolerability beyond what the engineered dual agonists already show.
- Our read
- A real appetite hormone that mainly matters as the blueprint for dual agonists, not as a finished drug itself. Oxyntomodulin reduces appetite in short studies, but its rapid breakdown means the action has moved to the engineered glucagon/GLP-1 drugs modeled on it.
The mechanism
How it works.
Oxyntomodulin is a gut hormone made in the same intestinal cells as GLP-1 and released after eating. It is a weak agonist at two receptors at once: the GLP-1 receptor, where it curbs appetite and slows stomach emptying, and the glucagon receptor, where it nudges energy expenditure and liver fat handling up. Combining appetite suppression with higher energy use is exactly the logic behind the engineered glucagon/GLP-1 dual agonists, but oxyntomodulin itself is broken down within minutes, so it has not become a drug on its own.
Safety & regulatory boundary
The consequential part.
Oxyntomodulin is not an approved drug. Human studies are short and small, and its rapid breakdown limits it as a treatment. Research-labeled or compounded oxyntomodulin is not an approved product, and its biology does not establish a proven weight-loss therapy. The engineered dual agonists it inspired are separate products with their own evidence.
What's next
What we're watching.
Longer-acting oxyntomodulin analogs, and how the engineered dual agonists it inspired perform in late-stage trials.
Context
Why this is discussed.
Oxyntomodulin is the natural model for the glucagon/GLP-1 dual agonists that are now among the most closely watched obesity drugs, which keeps interest in the original hormone high.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · NA · RECRUITING · 2026-04-24
ClinicalTrials.gov · NA · COMPLETED · 2025-06-04
ClinicalTrials.gov · NA · COMPLETED · 2020-02-03
ClinicalTrials.gov · NA · COMPLETED · 2020-05-20
ClinicalTrials.gov · NA · COMPLETED · 2024-07-05
ClinicalTrials.gov · NA · COMPLETED · 2024-10-30
ClinicalTrials.gov · PHASE1 · COMPLETED · 2017-08-01
ClinicalTrials.gov · NA · RECRUITING · 2022-11-01
Indexed literature (PubMed)12
Hong SH et al. · Curr Opin Endocrinol Diabetes Obes · 2024
Gasbjerg LS et al. · Physiol Rev · 2026
Holst JJ · Annu Rev Physiol · 1997
Sandoval DA et al. · Physiol Rev · 2015
Holst JJ et al. · Peptides · 2025
Holst JJ et al. · Peptides · 2018
Chaudhri OB et al. · Annu Rev Physiol · 2008
Chaudhri OB et al. · Int J Obes (Lond) · 2008
Camilleri M et al. · Metab Syndr Relat Disord · 2018
Kueh MTW et al. · J Physiol · 2025
Lafferty RA et al. · Front Endocrinol (Lausanne) · 2021
Wynne K et al. · Nat Clin Pract Endocrinol Metab · 2006
Keep reading